-
Je něco špatně v tomto záznamu ?
Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable
R. Lakomy, T. Kazda, I. Selingerova, A. Poprach, P. Pospisil, R. Belanova, P. Fadrus, M. Smrcka, V. Vybihal, R. Jancalek, I. Kiss, K. Muckova, M. Hendrych, A. Knight, J. Sana, P. Slampa, O. Slaby,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
MMCI, 00209805 and FNBr, 65269705, NU20-03-00148 and NV19-05-00410
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Directory of Open Access Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The aim of this retrospective study is to assess the incidence, localization, and potential predictors of rapid early progression (REP) prior to initiation of radiotherapy in newly diagnosed glioblastoma patients and to compare survival outcomes in cohorts with or without REP in relation to the treatment. METHODS: We assessed a consecutive cohort of 155 patients with histologically confirmed irradiated glioblastoma from 1/2014 to 12/2017. A total of 90 patients with preoperative, postoperative, and planning MRI were analyzed. RESULTS: Median age 59 years, 59% men, and 39 patients (43%) underwent gross total tumor resection. The Stupp regimen was indicated to 64 patients (71%); 26 patients (29%) underwent radiotherapy alone. REP on planning MRI performed shortly prior to radiotherapy was found in 46 (51%) patients, most often within the surgical cavity wall, and the main predictor for REP was non-radical surgery (p < 0.001). The presence of REP was confirmed as a strong negative prognostic factor; median overall survival (OS) in patients with REP was 10.7 vs. 18.7 months and 2-year survival was 15.6% vs. 37.7% (hazard ratio HR 0.53 for those without REP; p = 0.007). Interestingly, the REP occurrence effect on survival outcome was significantly different in younger patients (≤ 50 years) and older patients (> 50 years) for OS (p = 0.047) and non-significantly for PFS (p = 0.341). In younger patients, REP was a stronger negative prognostic factor, probably due to more aggressive behavior. Patients with REP who were indicated for the Stupp regimen had longer OS compared to radiotherapy alone (median OS 16.0 vs 7.5; HR = 0.5, p = 0.022; 2-year survival 22.3% vs. 5.6%). The interval between surgery and the initiation of radiotherapy were not prognostic in either the entire cohort or in patients with REP. CONCLUSION: Especially in the subgroup of patients without radical resection, one may recommend as early initiation of radiotherapy as possible. The phenomenon of REP should be recognized as an integral part of stratification factors in future prospective clinical trials enrolling patients before initiation of radiotherapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20021703
- 003
- CZ-PrNML
- 005
- 20201204092511.0
- 007
- ta
- 008
- 201125s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/diagnostics10090676 $2 doi
- 035 __
- $a (PubMed)32899528
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Lakomy, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 245 10
- $a Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable / $c R. Lakomy, T. Kazda, I. Selingerova, A. Poprach, P. Pospisil, R. Belanova, P. Fadrus, M. Smrcka, V. Vybihal, R. Jancalek, I. Kiss, K. Muckova, M. Hendrych, A. Knight, J. Sana, P. Slampa, O. Slaby,
- 520 9_
- $a BACKGROUND: The aim of this retrospective study is to assess the incidence, localization, and potential predictors of rapid early progression (REP) prior to initiation of radiotherapy in newly diagnosed glioblastoma patients and to compare survival outcomes in cohorts with or without REP in relation to the treatment. METHODS: We assessed a consecutive cohort of 155 patients with histologically confirmed irradiated glioblastoma from 1/2014 to 12/2017. A total of 90 patients with preoperative, postoperative, and planning MRI were analyzed. RESULTS: Median age 59 years, 59% men, and 39 patients (43%) underwent gross total tumor resection. The Stupp regimen was indicated to 64 patients (71%); 26 patients (29%) underwent radiotherapy alone. REP on planning MRI performed shortly prior to radiotherapy was found in 46 (51%) patients, most often within the surgical cavity wall, and the main predictor for REP was non-radical surgery (p < 0.001). The presence of REP was confirmed as a strong negative prognostic factor; median overall survival (OS) in patients with REP was 10.7 vs. 18.7 months and 2-year survival was 15.6% vs. 37.7% (hazard ratio HR 0.53 for those without REP; p = 0.007). Interestingly, the REP occurrence effect on survival outcome was significantly different in younger patients (≤ 50 years) and older patients (> 50 years) for OS (p = 0.047) and non-significantly for PFS (p = 0.341). In younger patients, REP was a stronger negative prognostic factor, probably due to more aggressive behavior. Patients with REP who were indicated for the Stupp regimen had longer OS compared to radiotherapy alone (median OS 16.0 vs 7.5; HR = 0.5, p = 0.022; 2-year survival 22.3% vs. 5.6%). The interval between surgery and the initiation of radiotherapy were not prognostic in either the entire cohort or in patients with REP. CONCLUSION: Especially in the subgroup of patients without radical resection, one may recommend as early initiation of radiotherapy as possible. The phenomenon of REP should be recognized as an integral part of stratification factors in future prospective clinical trials enrolling patients before initiation of radiotherapy.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Selingerova, Iveta $u Research Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
- 700 1_
- $a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Pospisil, Petr $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Belanova, Renata $u Department of Radiology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Fadrus, Pavel $u Department of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Smrcka, Martin $u Department of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Vybihal, Vaclav $u Department of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Jancalek, Radim $u Department of Neurosurgery, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic. Department of Neurosurgery, St. Anne's University Hospital Brno, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Muckova, Katarina $u Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Hendrych, Michal $u First Department of Pathology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, 656 91 Brno, Czech Republic.
- 700 1_
- $a Knight, Andrea $u Department of Pathological Physiology, Faculty of Medicine, Gamma Delta T Cell Laboratory, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Sana, Jiri $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic. Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic. Department of Biology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 773 0_
- $w MED00195450 $t Diagnostics (Basel, Switzerland) $x 2075-4418 $g Roč. 10, č. 9 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32899528 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201204092509 $b ABA008
- 999 __
- $a ind $b bmc $g 1591412 $s 1112375
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 10 $c 9 $e 20200905 $i 2075-4418 $m Diagnostics $n Diagnostics $x MED00195450
- GRA __
- $a MMCI, 00209805 and FNBr, 65269705, NU20-03-00148 and NV19-05-00410 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20201125
